The most significant factors that lead to cancer-related death in breast cancer (BC) patients include drug resistance, migration, invasion, and metastasis. Several signaling pathways are involved in the development of BC. The different types of BC are initially sensitive to chemotherapy, and drug resistance can occur through multiple molecular mechanisms. Regardless of developing targeted Therapy, due to the heterogenic nature and complexity of drug resistance, it is a major clinical challenge with the low survival rate in BC patients. The deregulation of several signaling pathways, particularly the Hippo pathway (HP), is one of the most recent findings about the molecular mechanisms of drug resistance in BC, which are summarized in this review. Given that HP is one of the recent cancer research hotspots, this review focuses on its implication in BC drug resistance. Unraveling the different molecular basis of HP through its crosstalk with other signaling pathways, and determining the effectiveness of HP inhibitors can provide new insights into possible therapeutic strategies for overcoming chemoresistance in BC.

中文翻译：

---

乳腺癌耐药性：解码 Hippo 通路串扰的作用

导致乳腺癌（BC）患者癌症相关死亡的最重要因素包括耐药性、迁移、侵袭和转移。 BC 的发生涉及多种信号通路。不同类型的乳腺癌最初对化疗敏感，并且可通过多种分子机制发生耐药性。无论开发何种靶向治疗，由于耐药性的异质性和复杂性，BC患者的低生存率是一个重大的临床挑战。多种信号通路的失调，特别是 Hippo 通路 (HP)，是关于 BC 耐药分子机制的最新发现之一，本综述对此进行了总结。鉴于HP是近年来癌症研究的热点之一，本综述重点关注其在BC耐药性中的意义。通过 HP 与其他信号通路的串扰来揭示 HP 的不同分子基础，并确定 HP 抑制剂的有效性，可以为克服 BC 化疗耐药的可能治疗策略提供新的见解。